|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
|
BACK TO LIST |
|
|
|
|||||||||||||||||||||||||
| Test | 08 Aug 2023 | Reference Range | Unit |
|---|---|---|---|
| Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | 4 - 6 | % |
| Glucose [Mass/volume] in Blood | 157.5 H | 70 - 140 | mg/dL |
| Urea nitrogen [Mass/volume] in Blood | 7.9 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Blood | 0.5 L | 0.6 - 1.1 | mg/dL |
| Calcium [Mass/volume] in Blood | 9.7 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Blood | 141.3 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Blood | 3.9 | 3.5 - 5 | mmol/L |
| Chloride [Moles/volume] in Blood | 105.2 | 98 - 108 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Blood | 25.3 | 22 - 29 | mmol/L |
| Cholesterol [Mass/volume] in Serum or Plasma | 243.7 H | 239 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 225.9 H | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 177.6 H | 0 - 130 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 20.9 L | 40 - 60 | mg/dL |
| Microalbumin/Creatinine [Mass Ratio] in Urine | 15.2 | 0 - 30 | mg/g |
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| The patient shows persistent hyperglycemia with normal HbA1c, suggesting possible postprandial elevations or impaired glucose tolerance. There is marked dyslipidemia (high total cholesterol, LDL, triglycerides, and low HDL), increasing cardiovascular risk. Renal function appears preserved (normal urea, low creatinine likely due to low muscle mass), and microalbumin/creatinine ratio is normal. Electrolytes and calcium are within normal limits. Recommend clinical correlation for diabetes and aggressive management of lipid abnormalities. |